Table 3.
Frequencies for CYP2C9 variant alleles in patients with acute gastrointestinal bleeding secondary to NSAID and in control individuals who reported no adverse effects during NSAID therapy
| Variant allele | Bleeding patients num, (%) | Control patients num, (%) | Crude OR | 95% CI | P |
|---|---|---|---|---|---|
| CYP2C9*1 | 128 (68.1) | 193 (77.8) | 0.61 | 0.39–0.95 | 0.022 |
| CYP2C9*2 | 44 (23.4) | 34 (13.7) | 1.92 | 1.14–3.25 | 0.009 |
| CYP2C9*3 | 16 (8.5) | 21 (8.5) | 1.01 | 0.48–2.08 | 0.987 |
| Total | 188 (100) | 248 (100) | – | – | – |